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Abstract  
Background and Aims 
Colorectal cancer located at different anatomical subsites may have distinct etiologies and 
risk factors. Previous studies that have examined this hypothesis have yielded inconsistent 
results, possibly because most have been of insufficient size to identify heterogeneous 
associations with precision.  
Methods 
In the European Prospective Investigation into Cancer and Nutrition study, we used 
multivariable joint Cox proportional hazards models, which accounted for tumors at different 
anatomical sites (proximal colon, distal colon, and rectum) as competing risks, to examine the 
relationships between 14 established/suspected lifestyle, anthropometric, and 
reproductive/menstrual risk factors with colorectal cancer risk. Heterogeneity across sites was 
tested using Wald tests. 
Results  
After 14.9 years (median) follow-up of 521,330 men and women, 6,291 colorectal cancer 
cases occurred. Physical activity was inversely related to proximal colon and distal colon 
cancer, but not to rectal cancer (P-heterogeneity=0.03). Height was positively associated with 
proximal and distal colon cancer only, but not rectal cancer (P-heterogeneity=0.0001). For 
men, but not women, heterogeneous relationships were observed for body mass index (P-
heterogeneity=0.008) and waist circumference (P-heterogeneity=0.03), with weaker positive 
associations found for rectal cancer, compared to proximal and distal colon cancer. Current 
smoking was associated with a greater risk of rectal and proximal colon cancer, but not distal 
colon cancer (P-heterogeneity=0.05). No heterogeneity by anatomical site was found for 
alcohol consumption, diabetes, nonsteroidal anti-inflammatory drug use, and 
reproductive/menstrual factors. 
Conclusions  
The physical activity, anthropometry, and smoking relationships with colorectal cancer risk 
differed by subsite, supporting the hypothesis that tumors in different anatomical regions may 
have distinct etiologies.   
Keywords 
Colorectal cancer; risk factors; anatomical subsite; heterogeneity 
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Introduction 
 Colorectal cancer (CRC) is one of the most frequently occurring malignancies 
worldwide. In 2012, 746,000 and 614,000 new cases were diagnosed globally in men (third 
most common cancer) and in women (second most common cancer), respectively1. 
Colorectal tumors at different anatomical sites have variable clinical characteristics2. In the 
proximal colon, tumors typically present at a later stage with a poorer prognosis than those in 
the distal colon and rectum3, 4. Women are more likely to develop cancers in the proximal 
colon, while in men cancers are more common in the distal colon region5. In addition, with 
advancing age, a greater proportion of colorectal tumors are located in the proximal colon, 
with a reduced proportion of rectal tumors6.   
 
 Molecular heterogeneity has also been found for CRC tumors across anatomical sites. 
CpG island methylator phenotype (CIMP)-high, microsatellite instability (MSI)-high, and 
PIK3CA and BRAF mutations are most commonly found in the proximal colon region, with a 
linear decrease in frequency across the distal colon and rectum regions7. KRAS mutations 
have been found to be most common in the caecum region of the proximal colon, compared 
to other bowel regions7. TP53 mutations are more frequent in tumors in the distal colon and 
rectum, compared to the proximal colon8, 9. 
 
CRC tumors at different anatomical locations may also have differential etiologies 
and risk factors6, 8, 10, 11. Previous studies that have examined this hypothesis have yielded 
inconsistent results, possibly because most have been of insufficient size to identify 
heterogeneous associations with precision. We, therefore, undertook a comprehensive 
investigation of how 14 established or suspected lifestyle, anthropometric, and reproductive 
and menstrual risk factors are associated with tumors located at the three main anatomical 
sites (proximal colon, distal colon, and rectum) in the European Prospective Investigation 
into Cancer and Nutrition (EPIC) cohort, with >520,000 participants. The large number of 
incident CRC cases (>6,200) affords high statistical power to compare risk factor associations 
across tumor anatomical sites. 
 
Methods 
Study Population 
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EPIC is a multicenter prospective cohort of 521,448 participants mostly aged 35 years 
or above, who were recruited between 1992 and 2000, predominantly from the general 
population of 10 European countries (Denmark, France, Germany, Greece, Italy, the 
Netherlands, Norway, Spain, Sweden, and the United Kingdom)12. Written informed consent 
was provided by all study participants, and ethical approval for EPIC was provided by the 
International Agency for Research on Cancer and local participating centers. Participants 
with cancer diagnoses prior to recruitment (n=29,456); those in the highest and lowest 1% of 
the distribution for the ratio of energy intake to estimated energy requirement (n=9,573); and 
those with missing information on alcohol consumption and follow-up (n=6,259) were 
excluded from analyses. Additional exposure specific exclusions were applied when there 
was missing information for the risk factor of interest.  
 
Exposures 
The 14 CRC risk factors, all measured at recruitment, considered in the current 
analysis were: alcohol consumption (per 15 g/day); ever NSAID use (no, yes); physical 
activity index (inactive, moderately inactive, moderately active, active); prevalent diabetes 
(no, yes); smoking status (never, former, current); BMI (per 5 kg/m2); height (per 10 cm); 
waist circumference (per 5 cm); waist-to-hip-ratio (per 0.05); and in women only, age at 
menarche (<12, 12-13, 14-15, ≥15 years); age at menopause (≤50, 51-52, 53-54, ≥55 years); 
ever OC use (never, ever); ever MHT use (never, ever); and duration of MHT use (never 
users, <2, 2-<5, 5-<8, ≥8 years). In secondary analyses, we investigated the relationships by 
anatomical subsite for alcohol consumption from wine (per 15 g/day), beer (per 15 g/day), 
and spirits liquors (per 3 g/day). Full details of measurements are detailed in the 
Supplementary Methods. 
 
Follow-Up for Cancer Incidence and Vital Status 
Cancer incidence was determined through record linkage with regional cancer 
registries or via a combination of methods, including the use of health insurance records, 
contacts with cancer and pathology registries, and active follow-up. CRC cases were defined 
using the Tenth Revision of the International Classification of Diseases (ICD-10) and the 
Second Revision of the International Classification of Diseases for Oncology (ICDO-2). 
Proximal colon cancer included those within the caecum, appendix, ascending colon, hepatic 
flexure, transverse colon, and splenic flexure (C18.0–18.5). Distal colon cancer included 
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those within the descending (C18.6) and sigmoid (C18.7) colon. Cancer of the rectum 
included cancer occurring at the recto-sigmoid junction (C19) and rectum (C20).  
 
Statistical analysis 
 Hazard ratios (HRs) and the corresponding 95% confidence intervals (95%CIs) for 
the 14 risk factors and CRC were estimated using Cox proportional hazards models. Age was 
used as the time-scale in all models. Time at entry was age at recruitment. Exit time was age 
at whichever of the following came first: CRC diagnosis, death, or the last date at which 
follow-up was considered complete in each center. For the analyses by anatomical site, HRs 
and 95%CI were estimated using multivariable joint Cox proportional hazards model which 
accounted for tumors located at different anatomical sites as competing risks13. Heterogeneity 
across sites was tested using Wald tests. Full details on the statistical methods are in the 
Supplementary Methods and are detailed by Xue et al.13. Separate models were run for body 
size measurements and CRC for men and women due to a priori knowledge that the 
relationship differs by sex14. To determine whether the lifestyle risk factors and CRC 
relationships differed by sex, we included an interaction term for sex (multiplicative scale) in 
the model. The statistical significance of the cross-product terms was evaluated using the 
likelihood ratio test. Due to no heterogeneity being found by sex for smoking status (P-
interaction=0.36), physical activity (P-interaction=0.71), alcohol consumption (P-
interaction=0.45), diabetes (P-interaction=0.83), and NSAID use (P-interaction=0.34), men 
and women were analyzed together. Multivariable models were, where appropriate, mutually 
adjusted. We also conducted sensitivity analyses separating tumors located in the caecum 
(C18) into an additional anatomical site and examining heterogeneity in the relationships to 
each risk factor across four anatomical sites (caecum colon versus proximal colon versus 
distal colon versus rectum). Statistical tests used in the analysis were all two-sided and a P-
value <0.05 was considered statistically significant.  
 
Results 
During a median follow-up of 14.9 years, 6,291 CRC cases occurred (2,718 in men 
and 3,573 in women). Of these, 1,877 were located in the proximal colon, 1,743 in the distal 
colon, and 2,094 in the rectum. Table 1 shows the characteristics of participants included in 
the analysis.  
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Alcohol consumption, prevalent diabetes, and smoking were associated with a greater 
risk of CRC, and ever NSAID use and physical activity were associated with a lower risk 
(Figure 1). For physical activity, compared to being inactive, the physically active group had 
a lower risk of developing CRC (HR=0.90, 95%CI: 0.82-0.98; P-trend=0.01). This inverse 
association was most evident for proximal colon cancers (HR=0.74, 95%CI: 0.63-0.87; P-
trend=0.0004), while the estimates were not statistically significant for distal colon or rectal 
cancers (P-heterogeneity for proximal-distal-rectal=0.03). Smoking was associated with the 
development of CRC (current smokers versus never smokers, HR=1.19, 95%CI: 1.11-1.28; 
P-trend<0.0001). By anatomical site, heterogeneity was observed, with current smoking 
(versus never smokers) being associated with elevated risks of proximal colon (HR=1.19, 
95%CI: 1.05-1.34) and rectal cancers (HR=1.27, 95%CI: 1.14-1.42), but not distal colon 
cancer (HR=1.08, 95%CI: 0.94-1.23) (P-heterogeneity across three sites=0.05; P-
heterogeneity proximal and distal colon=0.04). Former smoking was associated with a greater 
risk of developing distal colon cancer (versus never smokers, HR=1.27, 95%CI: 1.13-1.43). 
Greater alcohol consumption was associated with elevated risk of CRC (HR per 15 g/day 
increment, HR=1.05, 95%CI: 1.03-1.07). Although the test for heterogeneity was not 
statistically significant (P-heterogeneity=0.15 for proximal-distal-rectal), positive 
associations were found for distal colon and rectal cancer, but not for proximal colon cancer. 
No heterogeneity was observed for tumors located at different anatomical subsites for alcohol 
from wine, beer, and spirits/liquors when analyzed separately (all P-heterogeneities>0.05) 
(Table S1). Prevalent diabetes at baseline (yes versus no) was associated with higher CRC 
risk (HR=1.28, 95%CI: 1.12-1.47), with similar positive relationships found across 
anatomical sites (P-heterogeneity>0.70), although the association for rectal cancer was not 
statistically significant. Ever use of NSAIDs was associated with a lower CRC risk (versus 
never use, HR=0.85, 95%CI: 0.74-0.99), with no heterogeneity observed for tumors located 
at different anatomical sites (all P-heterogeneity>0.30). 
 
For men and women, higher BMI, height, waist circumference, and waist-to-hip ratio 
were all associated with greater risk of CRC (Figure 2). For men, the positive relationship for 
BMI was weaker for rectal cancer (HR per 5 kg/m2, HR=1.10, 95%CI: 1.01-1.20), compared 
to proximal colon (HR per 5 kg/m2, HR=1.31, 95%CI: 1.18-1.47) and distal colon cancers 
(HR per 5 kg/m2, HR=1.32, 95%CI: 1.20-1.45) (P-heterogeneity=0.008), but no 
heterogeneity was found between tumors in the proximal and distal colon (P-
heterogeneity=0.94). Also in men, the positive waist circumference association was weaker 
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for tumors located in the rectum (HR per 5 cm, HR=1.06, 95%CI: 1.03-1.09), than for tumors 
in the proximal (HR per 5 cm, HR=1.11, 95%CI: 1.07-1.16) and distal colon (HR per 5 cm, 
HR=1.12, 95%CI: 1.08-1.16) (P-heterogeneity=0.03), but no heterogeneity was found across 
the colon (proximal versus distal P-heterogeneity=0.78). The positive association between 
waist-to-hip ratio and CRC for men and women was consistent across all anatomical sites (all 
P-heterogeneities>0.60). For men and women, height was not associated with rectal cancer 
(men HR per 10 cm, HR=0.97, 95%CI: 0.88-1.06; women HR per 10 cm, HR=0.92, 95%CI: 
0.83-1.03), but was positively related to both proximal colon and distal colon cancers (P-
heterogeneity=0.0001 for men and P-heterogeneity<0.0001 for women). The association of 
height with colon cancer did not differ between proximal and distal colon in men (P-
heterogeneity=0.24), but there was some suggestion of heterogeneity for women (P-
heterogeneity=0.05), with a stronger positive association observed for proximal colon cancer 
(HR per 10 cm, HR=1.30, 95%CI: 1.17-1.43) than for distal colon cancer (HR per 10 cm, 
HR=1.11, 95%CI: 0.99-1.25). For women, no heterogeneity by subsite was observed for the 
other anthropometric measurements, with similar strength associations found for BMI, waist 
circumference, and waist-to-hip ratio across tumors at the three anatomical sites (all P-
heterogeneities>0.05). 
 
Ever MHT use versus never use was associated with a lower risk of CRC (HR=0.90, 
95%CI: 0.83-0.97), with no evidence of heterogeneity across subsites (P-
heterogeneities>0.16) (Figure 3). Duration of MHT use was inversely associated with CRC 
risk (P-trend=0.01), with no heterogeneity found by anatomical site (P-heterogeneity>0.05). 
Age at menarche and ever OC use was not associated with CRC and no heterogeneity was 
observed across anatomical sites (P-heterogeneity>0.05). Older age (≥55 years) versus 
younger age at menopause (≤50 years) was associated with elevated CRC risk (HR=1.20, 
95%CI: 1.03-1.38), with similar relationships observed by anatomical site (P-
heterogeneity>0.40).  
 
When tumors located in the caecum were considered as an additional subsite end-
point, a similar pattern of heterogeneous relationships was considered across the four subsites 
(caecum colon, proximal colon, distal colon, and rectum) (Tables S2 to S4). 
 
Discussion 
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 In this multi-country prospective study, we found heterogeneous relationships by 
tumor site for physical activity, smoking, and anthropometric measurements. Low levels of 
physical activity and greater height and BMI were primarily associated with an increased risk 
of distal or proximal colon cancer, with weaker or null relationships found for rectal cancer. 
Current smoking was associated with an increased risk of proximal colon and rectal cancer, 
while no heterogeneity by anatomical site was found for alcohol consumption, prevalent 
diabetes, NSAIDs use, and, in women, reproductive and menstrual factors. 
 
 For overall CRC, we observed the expected pattern of risk factor associations. Greater 
adiposity and height were associated with elevated CRC risk, as were higher alcohol 
consumption, smoking, prevalent diabetes, and later age at menopause. Conversely, being 
physically active, and use of NSAIDs and MHT were associated with lower risk of 
developing CRC. Our analysis benefited from the large number of incident CRC cases which 
accrued during the longer follow-up period, which allowed well-powered analyses for the 14 
risk factors by tumor anatomical site. Recently, a similar analysis of CRC risk factors by 
anatomical site was undertaken in a large UK cohort, with no heterogeneity found for the 
considered risk factors by tumor anatomical site15; however, that study included only women, 
so it is uncertain whether the findings are generalizable to men15. Previous studies which 
have investigated heterogeneity in the association between major risk factors and colorectal 
anatomical subsites in men and women had smaller numbers of cases compared to our 
analysis, and may have been constrained by insufficient statistical power to identify weak-to-
moderate strength heterogeneous associations16, 17. In the current study, which included men 
and women, we observed heterogeneous relationships between several risk factors and 
tumors across different anatomical sites.  
 
We found that greater physical activity was similarly related to lower risks of 
developing tumors in the proximal and distal colon regions, findings consistent with other 
large prospective studies15, 17, and a meta-analysis of 21 studies18. Physical activity was not, 
however, related to rectal cancer risk, a result inconsistent with a recent participant-level 
pooled analysis which reported an inverse relationship between physical activity and rectal 
cancer incidence19, but in accordance with a joint Nurses’ Health Study and Health 
Professionals Follow-up Study analysis10. The biological mechanisms through which physical 
activity potentially lowers colon cancer risk, but not rectal cancer risk, are uncertain. Being 
physically active is associated with less weight gain and body fatness20, and therefore has a 
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beneficial effect on CRC risk21. However, in our study, we found that greater BMI and waist 
circumference were risk factors for colon and, albeit more weakly, for rectal cancer. Greater 
physical activity has also been associated with lower insulin levels and beneficial effects on 
inflammatory pathways and dyslipidemia, including lowering levels of circulating 
triglycerides22-24. Previous meta-analyses suggest that C-peptide (a marker of insulin 
secretion), C-reactive protein (a nonspecific marker of systemic inflammation), and 
triglycerides are positively associated with colon, but not with rectal cancer25-28. This 
suggests that any beneficial effects of physical exercise on insulin (or correlated metabolic 
markers), inflammatory, and lipid pathways would be more likely to influence tumors in the 
colon, and not in the rectum, potentially explaining the null result we observed for physical 
activity with rectal cancer.  
 
Our finding that higher BMI was more strongly related to greater CRC risk among 
men than among women is in accordance with a large body of epidemiological evidence21, 29, 
30
. We observed heterogeneous relationships for anthropometric measurements by anatomical 
site, particularly for men. For BMI, the positive relationship found among men was weaker 
for rectal cancer compared to tumors in the colon. A meta-analysis of prospective studies also 
observed that, for men, greater BMI was more weakly associated with rectal cancer (relative 
risk [RR] per 5 kg/m2 unit increase in BMI=1.12, 95%CI: 1.09-1.16) than with colon cancer 
(RR per 5 kg/m2 unit increase in BMI=1.30, 95%CI: 1.25-1.35)21. A moderately weaker 
positive relationship was found for waist circumference and rectal cancer in men compared to 
colonic subsites, yet for waist-to-hip ratio no heterogeneity by anatomical site was observed. 
For men and women, height was associated with colon cancer, but not with rectal cancer. 
This null result for rectal cancer is inconsistent with other large prospective cohort studies 
and a meta-analysis which found a positive association for height and rectal cancer31, 32. 
Additionally, positive relationships of similar magnitude were found for both colon and rectal 
cancer in a Mendelian randomization analysis33. 
 
Current smoking was related to an elevated risk of proximal colon and rectal cancers, 
but not distal colon cancer. A similar pattern of results for smoking history as found in the 
Nurses’ Health Study, with 40 pack-years of smoking (versus none) only being positively 
associated with proximal colon (HR=1.31, 95%CI: 1.16-1.48) and rectal cancer (HR=1.27, 
95%CI: 1.05-1.53), but not distal colon cancer (HR=1.04, 95%CI: 0.88-1.23)17. MSI-high, 
BRAF mutation-positive, and CIMP-positive tumors, are more common in the proximal colon 
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region compared to the distal colon7, and have been positively associated with cigarette 
smoking11. However, these molecular characteristics are even less common for malignant 
tumors in the rectum, the subsite for which we observed the strongest positive relationship 
with smoking. Additionally, a positive relationship was observed for former smokers and 
distal colon cancer which is inconsistent with these molecular characteristics explaining these 
findings. 
 
The current investigation is the largest study to date to comprehensively investigate 
the relationships between CRC risk factor by anatomical site in both men and women. 
Limitations of our analysis were that all of the considered risk factors were measured once at 
baseline, and due to multiple known or suspected CRC risk factors being simultaneously 
investigated, some of our results could have been chance findings. Finally, our study would 
have been enhanced with information on tumor molecular features. 
 
In conclusion, heterogeneous relationships across tumors located in the proximal 
colon, distal colon, and rectum were observed for physical activity, anthropometric 
measurements, and smoking. These results, taken together with the varying biological and 
molecular features of tumors located across the colorectum, indicate that tumors in different 
anatomical regions may have distinct etiologies. 
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Figures and legends 
Figure 1. Multivariable-adjusted hazard ratios (HR) and 95% confidence intervals (CI) for 
colorectal cancer incidence for both sexes combined in relation to lifestyle factors, by 
anatomical site. 
For alcohol consumption, physical activity, and smoking status: Multivariable models–Cox 
regression using age as the underlying time variable and stratified by sex, center, and age at 
recruitment. Models mutually adjusted, and additionally adjusted for body mass index, 
height, education level, ever use of menopausal hormone therapy, and intakes of alcohol, red 
and processed meats, calcium, and fiber. For ever nonsteroidal anti-inflammatory drug 
(NSAID) use and prevalent diabetes: Multivariable models–Cox regression using age as the 
underlying time variable and stratified by sex, center, and age at recruitment adjusted for 
body mass index, height, physical activity; smoking status and intensity; education level; ever 
use of menopausal hormone therapy; and intakes of alcohol, red and processed meats, 
calcium, and fiber. †Nonsteroidal anti-inflammatory drug (NSAID) use information only 
available from six centers-Cambridge, Utrecht, Heidelberg, Potsdam, Aarhus, Copenhagen. 
 
Figure 2. Multivariable-adjusted hazard ratios (HR) and 95% confidence intervals (CI) for 
colorectal cancer incidence for both sexes combined in relation to anthropometric measures, 
by anatomical site. 
Multivariable models only–Cox regression using age as the underlying time variable and 
stratified by center and age at recruitment, and adjusted for physical activity, smoking status 
and intensity, education level, ever use of menopausal hormone therapy, and intakes of 
alcohol, red and processed meats, calcium, and fiber. Multivariable model for height was 
further adjusted for body mass index. Multivariable models for body mass index, waist 
circumference, and waist-to-hip ratio were further adjusted for height. 
 
Figure 3. Multivariable-adjusted hazard ratios (HR) and 95% confidence intervals (CI) for 
colorectal cancer incidence in relation to reproductive and menstrual factors among women, 
by anatomical site. 
Multivariable models only–Cox regression using age as the underlying time variable and 
stratified by center and age at recruitment, and adjusted for body mass index, height, physical 
activity, smoking status and intensity, education level, ever use of menopausal hormone 
therapy, and intakes of alcohol, red and processed meats, calcium and fiber. MHT-
menopausal hormone therapy. 
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Table 1. Characteristics of participants at recruitment‡ 
  Both sexes 
  
Non-cases 
Colorectal 
cancer cases 
Colon proximal 
cancer cases 
Colon distal 
cancer cases 
Rectal cancer 
cases   
N 469,869 6,291 1,877 1,743 2,094 
Women (%) 70.3 56.8 64.4 56.0 50.7 
Age at recruitment (years) 51.2 (9.9) 57.3 (7.9) 58.2 (7.9) 56.9 (7.5) 56.6 (7.7) 
Alcohol consumption (g/day)  11.6 (16.8) 15.0 (20.2) 12.6 (18.4) 15.4 (20.5) 16.5 (21.4) 
Smoking status           
Never (%) 49.1 40.7 43.6 40.4 38.4 
Current (%) 22.4 24.1 22.8 22.3 26.0 
Ever nonsteroidal anti-inflammatory drug (NSAID) use           
Yes (%) 8.2 8.5 8.2 9.4 8.3 
Physical activity           
Inactive (%) 20.9 24.9 27.9 25.0 21.8 
Active (%) 17.9 18.4 15.6 18.7 21.4 
Prevalent diabetes           
Yes (%) 2.8 4.4 4.5 4.6 3.8 
Body mass index (kg/m2)      
Men 26.5 (3.6) 27.2 (3.8) 27.3 (4.0) 27.5 (3.8) 26.9 (3.6) 
Women 25.4 (4.6) 26.1 (4.6) 25.9 (4.5) 26.3 (4.7) 26.0 (4.5) 
Height (cm)      
Men 174.7 (7.4) 174.4 (7.1) 175.2 (7.1) 174.5 (7.3) 174.2 (7.0) 
Women 161.8 (6.8) 161.8 (6.6) 162.3 (6.2) 161.7 (6.6) 161.5 (6.4) 
Waist circumference (cm)      
Men 94.6 (10.2) 97.4 (10.2) 97.6 (10.4) 98.2 (10.5) 96.8 (9.9) 
Women 80.2 (11.5) 82.6 (11.7) 82.6 (11.5) 83.1 (12.1) 82.0 (11.7) 
Waist-to-hip ratio      
Men  0.94 (0.1) 0.96 (0.1) 0.95 (0.1) 0.96 (0.1) 0.96 (0.1) 
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Women 0.79 (0.1) 0.81 (0.1) 0.81 (0.1) 0.81 (0.1) 0.80 (0.1) 
Age at menarche (years) 13.1 (1.5) 13.2 (1.6) 13.2 (1.6) 13.2 (1.6) 13.2 (1.5) 
Age at menopause (years) 48.6 (5.0) 49.0 (5.0) 49.0 (5.0) 49.0 (4.8) 49.2 (5.1) 
Ever oral contraceptive (OC) use           
Yes (%) 58.8 47.5 45.3 48.2 51.9 
Ever menopausal hormone therapy (MHT) use           
Yes (%) 25.9 31.1 32.8 29.5 30.9 
Education           
Longer education (including university) 24.2 19.0 19.1 18.4 18.8 
Red and processed meat intake (g/day) 74.7 (51.0) 83.0 (52.7) 78.8 (51.3) 82.7 (52.3) 87.2 (53.5) 
Calcium intake (mg/day)  994.8 (409.4) 985.0 (398.5) 994.1 (392.6) 970.4 (393.6) 984.2 (401.3) 
Fibre intake (g/day)  22.8 (7.7) 22.6 (7.7) 22.5 (7.6) 22.5 (7.9) 22.8 (7.5) 
Mean and standard deviation unless stated otherwise.  
‡Based on participant numbers in the alcohol consumption models. 
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What You Need to Know 
Background 
• Previous research indicates that colorectal tumours located at different anatomical sites have 
distinct clinical and molecular characteristics.  
• It has also been hypothesized that colorectal cancer at different anatomical locations may 
have differential aetiologies and risk factors.  
• Previous epidemiological studies may have been underpowered to detect heterogeneous 
relationships by anatomical site. 
 
Findings 
• This was the largest study to date to comprehensively investigate the relationships between 
colorectal cancer risk factors by anatomical site in both men and women, with >520,000 
participants from 10 European countries included, and >6,200 incident colorectal cancer 
cases. 
• We found heterogeneous relationships across tumours located in the proximal colon, distal 
colon, and rectum for physical activity levels, anthropometric measurements, and smoking.  
 
Implications 
• These results highlight the importance of separating the colorectum into distinct entities with 
separate aetiologies.  
• Variability in the carcinogenic processes at different sites of the large-bowel may explain the 
complex risk factor-colorectal cancer relationships.  
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Methods  
Exposures 
The 14 colorectal cancer risk factors, all measured at recruitment, considered in the 
current analysis were: alcohol consumption (per 15 g/day increment); ever NSAID use (no, yes); 
physical activity index (inactive, moderately inactive, moderately active, active); prevalent 
diabetes (no, yes); smoking status (never, former, current); BMI (per 5 kg/m2 increment); height 
(per 10 cm increment); waist circumference (per 5 cm increment); waist-to-hip-ratio (per 0.05 
increment); and in women only, age at menarche (<12, 12 to 13, 14 to 15, ≥15 years); age at 
menopause (≤50, 51 to 52, 53 to 54, ≥55 years); ever OC use (never, ever); ever MHT use 
(never, ever); and duration of MHT use (never users, <2, 2-<5, 5-<8, ≥8 years). In secondary 
analyses, we investigated the relationships by anatomical subsite for alcohol consumption from 
wine (per 15 g/day increment), beer (per 15 g/day increment), and spirits liquors (per 3 g/day 
increment).  
 
With participants not wearing shoes, weight was measured to the nearest 0.1 kg and 
height was measured—dependent on the study center—to the nearest 0.1, 0.5, or 1.0 cm. Body 
mass index (BMI) was calculated as weight in kilograms divided by height in meters squared 
(kg/m2). Waist circumference was measured either at the narrowest torso circumference or at the 
midpoint between the lower ribs and iliac crest. Hip circumference was measured at the widest 
circumference (France; Italy; Spain; Bilthoven, The Netherlands; Greece; Malmö, Sweden) or 
over the buttocks (the United Kingdom; Utrecht, The Netherlands; Germany; Denmark). Waist-
to-hip ratio was calculated by dividing waist circumference by hip circumference. Standardized 
lifestyle and personal history questionnaires were collected at recruitment1, 2, before disease 
onset or diagnosis. Information on cigarette smoking habits included baseline smoking status 
(never, former, or current smoker). Overall physical activity (the sum/total of occupational 
physical activity and leisure time physical activity) was assessed from three questions referring 
to the past year and an index was derived by allocating individuals to four categories of overall 
activity (inactive, moderately inactive, moderately active and active)3. Information was collected 
on education, diabetes prevalence, oral contraceptive (OC) use, menopausal hormone therapy 
(MHT) use, age at menarche, age at menopause, and, in six centers (Cambridge, UK; Utrecht, 
The Netherlands; Heidelberg and Potsdam, Germany; Aarhus and Copenhagen, Denmark), 
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NSAID use (including aspirin). Diet over the previous 12 months was assessed at recruitment 
using validated country/centre-specific dietary questionnaires1, 2. Alcohol consumption at 
recruitment was calculated from the number of standard glasses of beer, wine, cider, sweet 
liquor, distilled spirits or fortified wines consumed per day/week reported during the 12 months 
prior to recruitment.  
 
Follow-Up for Cancer Incidence and Vital Status 
Cancer incidence was determined through record linkage with regional cancer registries 
(Denmark, Italy, the Netherlands, Norway, Spain, Sweden, and the United Kingdom) or via a 
combination of methods, including the use of health insurance records, contacts with cancer and 
pathology registries, and active follow-up through participants and their next of kin (France, 
Germany, and Greece). Colorectal cancer cases were defined using the Tenth Revision of the 
International Classification of Diseases (ICD-10) and the Second Revision of the International 
Classification of Diseases for Oncology (ICDO-2). Proximal colon cancer included those within 
the caecum, appendix, ascending colon, hepatic flexure, transverse colon, and splenic flexure 
(C18.0–18.5). Distal colon cancer included those within the descending (C18.6) and sigmoid 
(C18.7) colon. Cancer of the rectum included cancer occurring at the recto-sigmoid junction 
(C19) and rectum (C20).  
 
Statistical analysis 
 Hazard ratios (HRs) and the corresponding 95% confidence intervals (95%CIs) for the 14 
risk factors and CRC were estimated using Cox proportional hazards models. Age was used as 
the time-scale in all models. Time at entry was age at recruitment. Exit time was age at 
whichever of the following came first: colorectal cancer diagnosis, death, or the last date at 
which follow-up was considered complete in each center. Possible non-proportionality was 
assessed using an analysis of Schoenfeld residuals4, with no evidence of non-proportionality 
being detected. For the analyses by anatomical site, HRs and 95%CI were estimated using 
multivariable joint Cox proportional hazards model which accounted for tumors located at 
different anatomical sites as competing risks5. The heterogeneity in baseline risk of colorectal 
cancer subsites was addressed by stratified Cox models where each subsite was allowed to have 
its own baseline hazard function; the heterogeneity in association with risk factors across 
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subsites was assessed by including an interaction term between each risk factor and the 
indicators of colorectal cancer subsites and testing the statistical significance of the interaction 
terms. As a robust variance was used to address the competing risk between colorectal cancer 
subsites, a log-likelihood ratio test was no longer valid. We, therefore, used a global Wald-test 
based on the robust variance estimates obtained from a “sandwich” type of estimator. Full details 
on the statistical method  are in the Supplementary Methods and are detailed by Xue et al.5 
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Table S1. Multivariable-adjusted hazard ratios (HR) and 95% confidence intervals (CI) for colorectal cancer incidence for both sexes combined in 
relation to alcohol intake (overall and by source), by anatomical site 
    Both sexes 
      
Colorectal 
cancer   Colon proximal   Colon distal   Rectal 
    N cases Multivariable N cases Multivariable N cases Multivariable 
N 
cases Multivariable 
Alcohol 
Per 15g/day 6291 1.05 (1.03-1.07) 1877 1.01 (0.97-1.06) 1743 1.06 (1.02-1.10) 2094 1.07 (1.03-1.11) 
P-Heterogeneity proximal-distal-rectal 0.15 
P-Heterogeneity proximal-distal 0.12 
Alcohol from wine 
Per 15g/day 6291 1.03 (0.99-1.06) 1877 1.00 (0.93-1.07) 1743 1.05 (1.00-1.11) 2094 1.04 (0.99-1.09) 
P-Heterogeneity proximal-distal-rectal 0.46 
P-Heterogeneity proximal-distal 0.22 
Alcohol from beer 
Per 15g/day 6291 1.09 (1.05-1.13) 1877 1.03 (0.94-1.12) 1743 1.10 (1.03-1.17) 2094 1.11 (1.06-1.16) 
P-Heterogeneity proximal-distal-rectal 0.29 
P-Heterogeneity proximal-distal 0.21 
Alcohol from spirits/liquors 
Per 3g/day 6291 1.01 (1.00-1.03) 1877 1.00 (0.97-1.04) 1743 1.00 (0.96-1.03) 2094 1.02 (1.00-1.05) 
P-Heterogeneity proximal-distal-rectal 0.27 
  P-Heterogeneity proximal-distal 0.80 
Multivariable models only – Cox regression using age as the underlying time variable and stratified by sex, center, and age at recruitment. Models adjusted for body mass index, 
height, physical activity index, smoking status and intensity, education level attained, ever use of menopausal hormone therapy, and intakes of red and processed meats, dietary 
calcium, and fiber. 
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Table S2. Multivariable-adjusted hazard ratios (HR) and 95% confidence intervals (CI) for colorectal cancer incidence for both sexes combined in 
relation to lifestyle factors, by tumors in the colon caecum, colon proximal, colon distal, and rectum. 
    Both sexes 
N cases 
Colon caecum 
N cases 
Colon proximal 
N cases 
Colon distal 
N cases 
Rectal 
    Multivariable Multivariable Multivariable Multivariable 
Alcohol consumption 
Per 15g/day 720 1.00 (0.92-1.09) 1198 1.03 (0.97-1.08) 1743 1.06 (1.02-1.10) 2211 1.07 (1.04-1.11) 
P-Heterogeneity caecum-
proximal-distal-rectal 0.33 
Ever nonsteroidal anti-inflammatory drug (NSAID) use† 
No 257 1 587 1 587 1 802 1 
Yes 28 0.91 (0.61-1.35) 61 0.73 (0.50-1.05) 61 0.97 (0.74-1.26) 73 0.86 (0.67-1.09) 
P-Heterogeneity caecum-
proximal-distal-rectal 0.67 
Physical activity index 
Inactive 196 1 344 1 436 1 457 1 
Moderately inactive 231 0.88 (0.72-1.09) 383 0.72 (0.62-0.84) 588 0.93 (0.81-1.06) 662 0.97 (0.86-1.10) 
Moderately active 156 0.88 (0.69-1.13) 270 0.73 (0.60-0.87) 367 0.80 (0.69-0.94) 490 0.99 (0.87-1.15) 
Active 113 0.83 (0.64-1.08) 186 0.68 (0.56-0.83) 326 0.90 (0.76-1.05) 447 1.07 (0.93-1.24) 
P-trend 0.18 0.0003 0.06 0.29 
P-Heterogeneity caecum-
proximal-distal-rectal 0.02 
Prevalent diabetes  
No 559 1 1012 1 1464 1 1784 1 
Yes 23 1.29 (0.84-2.00) 54 1.33 (0.97-1.82) 72 1.34 (1.04-1.74) 72 1.21 (0.95-1.54) 
P-Heterogeneity caecum-
proximal-distal-rectal 0.94 
Smoking status 
Never 320 1 509 1 704 1 847 1 
Former 233 1.07 (0.89-1.27) 385 1.18 (1.03-1.36) 616 1.27 (1.13-1.43) 757 1.20 (1.09-1.33) 
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Current 151 1.12 (0.91-1.38) 289 1.25 (1.08-1.46) 388 1.08 (0.94-1.23) 582 1.27 (1.14-1.42) 
 
P-trend 0.27 0.0017 0.09 <0.0001 
  
P-Heterogeneity caecum-
proximal-distal-rectal 0.13 
For alcohol consumption, physical activity index, and smoking status: Multivariable models only – Cox regression using age as the underlying time variable and stratified by sex, 
center, and age at recruitment. Models mutually adjusted, and additionally adjusted for body mass index, height, education level attained, ever use of menopausal hormone therapy, 
and intakes of alcohol, red and processed meats, dietary calcium, and fiber.  
For ever nonsteroidal anti-inflammatory drug (NSAID) use and prevalent diabetes: Multivariable models only – Cox regression using age as the underlying time variable and 
stratified by sex, center, and age at recruitment adjusted for body mass index, height, physical activity index; smoking status and intensity; education level attained; ever use of 
menopausal hormone therapy; and intakes of alcohol, red and processed meats, dietary calcium, and fiber.  
† Nonsteroidal anti-inflammatory drug (NSAID) use information only available from six centers (Cambridge, UK; Utrecht, The Netherlands; Heidelberg and Potsdam, Germany; 
Aarhus and Copenhagen, Denmark). 
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Table S3. Multivariable-adjusted hazard ratios (HR) and 95% confidence intervals (CI) for colorectal cancer incidence for both sexes combined in 
relation to anthropometric measures, by tumors in the colon caecum, colon proximal, colon distal, and rectum. 
      
N cases 
Colon caecum 
N cases 
Colon proximal 
N cases 
Colon distal 
N cases 
Rectal 
      Multivariable Multivariable Multivariable Multivariable 
BMI                 
Men 
Per 5 kg/m2 250 1.41 (1.19-1.68) 437 1.26 (1.09-1.45) 760 1.32 (1.20-1.45) 1076 1.11 (1.02-1.03) 
P-Heterogeneity caecum-proximal-
distal-rectal 0.01 
Women 
Per 5 kg/m2 405 1.06 (0.94-1.19) 624 1.06 (0.97-1.16) 793 1.13 (1.04-1.22) 854 1.08 (1.01-1.16) 
P-Heterogeneity caecum-proximal-
distal-rectal 0.72 
Height 
Men 
Per 10 cm 250 1.43 (1.18-1.75) 437 1.22 (1.06-1.42) 763 1.20 (1.07-1.34) 1077 0.95 (0.86-1.04) 
P-Heterogeneity caecum-proximal-
distal-rectal <0.0001 
Women 
Per 10 cm 407 1.30 (1.11-1.52) 625 1.26 (1.11-1.45) 793 1.10 (0.99-1.25) 909 0.92 (0.83-1.03) 
P-Heterogeneity caecum-proximal-
distal-rectal 0.0003 
Waist circumference 
Men 
Per 5 cm 236 1.13 (1.06-1.20) 409 1.10 (1.05-1.16) 712 1.12 (1.08-1.17) 1006 1.06 (1.03-1.09) 
P-Heterogeneity caecum-proximal-
distal-rectal 0.05 
Women 
Per 5 cm 389 1.04 (0.99-1.09) 591 1.06 (1.02-1.10) 759 1.06 (1.02-1.09) 863 1.04 (1.00-1.07) 
P-Heterogeneity caecum-proximal-
distal-rectal 0.78 
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Waist-to-hip ratio 
 
Men 
Per 0.05 233 1.14 (1.04-1.25) 404 1.12 (1.04-1.21) 710 1.16 (1.09-1.22) 1001 1.13 (1.08-1.19) 
P-Heterogeneity caecum-proximal-
distal-rectal 0.93 
Women 
Per 0.05 389 1.04 (0.96-1.13) 591 1.10 (1.04-1.16) 757 1.06 (1.00-1.11) 861 1.07 (1.01-1.12) 
    
P-Heterogeneity caecum-proximal-
distal-rectal 0.62 
Multivariable models only – Cox regression using age as the underlying time variable and stratified by center and age at recruitment, and adjusted for physical activity index, 
smoking status and intensity, education level attained, ever use of menopausal hormone therapy, and intakes of alcohol, red and processed meats, dietary calcium, and fiber. 
Multivariable model for height was further adjusted for body mass index. Multivariable models for body mass index, waist circumference, and waist-to-hip ratio were further 
adjusted for height. 
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Table S4. Multivariable-adjusted hazard ratios (HR) and 95% confidence intervals (CI) for colorectal cancer incidence among women in relation to 
reproductive and menstrual characteristics, by tumors in the colon caecum, colon proximal, colon distal, and rectum. 
N cases 
Colon caecum 
N cases 
Colon proximal 
N cases 
Colon distal 
N cases 
Rectal 
    Multivariable Multivariable Multivariable Multivariable 
Age at menarche (years) 
<12 13 1 23 1 28 1 22 1 
12 to 13 144 0.92 (0.52-1.63) 205 0.75 (0.48-1.15) 276 0.89 (0.61-1.32) 325 1.30 (0.84-2.00) 
14 to 15 203 0.77 (0.44-1.36) 348 0.75 (0.49-1.15) 460 0.92 (0.63-1.36) 545 1.34 (0.87-2.06) 
≥15 92 0.78 (0.43-1.41) 157 0.79 (0.51-1.23) 180 0.88 (0.59-1.32) 202 1.21 (0.78-1.89) 
P-trend 0.1372 0.9997 0.7919 0.9427 
P-Heterogeneity caecum-proximal-distal-
rectal 0.54 
Age at menopause (years) 
≤50 172 1 287 1 325 1 361 1 
51 to 52 53 1.06 (0.77-1.44) 78 0.93 (0.72-1.20) 110 1.18 (0.94-1.47) 106 1.03 (0.82-1.28) 
53 to 54 31 0.84 (0.57-1.23) 59 1.02 (0.77-1.35) 52 0.79 (0.58-1.06) 69 1.07 (0.82-1.39) 
≥55 46 1.52 (1.10-2.12) 48 1.05 (0.76-1.43) 56 1.17 (0.87-1.57) 67 1.32 (1.01-1.73) 
P-trend 0.1281 0.8442 0.8376 0.0794 
P-Heterogeneity caecum-proximal-distal-
rectal 0.44 
Ever oral contraceptive use 
No 276 1 380 1 492 1 532 1 
Yes 179 0.82 (0.66-1.01) 365 1.14 (0.97-1.34) 458 0.99 (0.86-1.14) 572 1.02 (0.90-1.17) 
P-Heterogeneity caecum-proximal-distal-
rectal 0.11 
Ever menopausal hormone therapy use 
Never 1 1 1 1 
Ever 0.90 (0.83-0.97) 0.95 (0.83-1.09) 0.82 (0.70-0.95) 0.88 (0.76-1.02) 
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P-Heterogeneity caecum-proximal-distal-
rectal 0.37 
Duration of menopausal hormone therapy use (years) 
Never users 288 1 467 1 642 1 705 1 
<2 46 1.08 (0.78-1.50) 68 0.93 (0.72-1.21) 81 0.79 (0.62-1.00) 122 1.07 (0.88-1.31) 
2-<5 34 0.94 (0.65-1.35) 60 0.92 (0.70-1.22) 65 0.74 (0.57-0.96) 75 0.77 (0.60-0.99) 
5-<8 21 1.00 (0.63-1.60) 39 1.12 (0.80-1.57) 37 0.79 (0.56-1.12) 45 0.90 (0.66-1.23) 
≥8 23 0.76 (0.49-1.19) 34 0.82 (0.57-1.18) 57 1.03 (0.78-1.37) 47 0.76 (0.55-1.04) 
P-trend 
 
0.34 
 
0.46 
 
0.21 
 
0.03 
P-Heterogeneity caecum-proximal-distal-
rectal 0.46 
Multivariable models only – Cox regression using age as the underlying time variable and stratified by center and age at recruitment, and adjusted for body mass index, height, 
physical activity index, smoking status and intensity, education level attained, ever use of menopausal hormone therapy, and intakes of alcohol, red and processed meats, dietary 
calcium and fiber.  
 
